Barry Rosen to Neoadjuvant Therapy
This is a "connection" page, showing publications Barry Rosen has written about Neoadjuvant Therapy.
Connection Strength
0.493
-
Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod SA, May T. The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. Int J Gynaecol Obstet. 2021 Jun; 153(3):417-423.
Score: 0.171
-
Altman AD, McGee J, May T, Lane K, Lu L, Xu W, Ghatage P, Rosen B. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. Gynecol Oncol. 2017 11; 147(2):257-261.
Score: 0.135
-
Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, Segev Y, Sun P, Narod SA. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol. 2014 Sep; 134(3):462-7.
Score: 0.109
-
Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, Tu D, Parulekar WR, Nankivell M, Kehoe S, Chi DS, Levine DA, Bernardini MQ, Rosen B, Oza A, Brown M, Neel BG. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A. 2021 06 22; 118(25).
Score: 0.044
-
May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, Ghatage P. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. Int J Gynecol Cancer. 2017 05; 27(4):668-674.
Score: 0.033